Ambrx Appoints Sonja Nelson as Chief Financial Officer
30 Juni 2021 - 2:00PM
Business Wire
Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company
using an expanded genetic code technology platform to create
Engineered Precision Biologics, today announced the appointment of
Sonja Nelson to Chief Financial Officer.
“I am delighted to welcome Sonja to Ambrx as we expand our
executive team, in light of our ongoing expansion,” said Feng Tian,
Ph.D., Chairman of the Board, President and CEO of Ambrx. “Sonja
brings a breadth of experience in financial operations, planning
and strategy from within the biotechnology industry. Her arrival at
Ambrx solidifies the company’s management team, and I look forward
to leaning on her experience as we transition into the next stages
of our company’s development.”
“I would like to thank Dr. Tian and the Ambrx team for welcoming
me to the company. I’m excited to be joining Ambrx and impressed by
the strength of the company’s development pipeline, and the
underlying technology behind it,” said Ms. Nelson. “I look forward
to leveraging my experience in the public biotech sector to help
provide Ambrx with the financial optionality it needs to further
its development pipeline.”
Ms. Nelson is an experienced financial executive, who joins
Ambrx with 10 years of executive experience within the
biotechnology industry. Most recently, she served as Chief
Financial Officer at NantKwest, now ImmunityBio (NASDAQ: IBRX).
Prior to NantKwest, Ms. Nelson was Vice President, Corporate
Controller for AltheaDx. Previously, Ms. Nelson served as Corporate
Controller at Cadence Pharmaceuticals (NASDAQ: CADX, which was
acquired by Mallinckrodt plc). Ms. Nelson also served as Director,
General Accounting at Cricket Communications, Inc. (acquired by
AT&T) between 2008 and 2012. She started her career at KPMG and
holds a bachelor’s degree in business administration with
specialization in taxation and auditing from the University of
Applied Sciences in Pforzheim, Germany. She is a Certified Public
Accountant.
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to create Engineered
Precision Biologics. These include next generation antibody drug
conjugates (ADCs), bispecifics, targeted immuno-oncology therapies,
novel cytokines to modulate the immune system, and long-acting
therapeutic peptides for metabolic and cardiovascular disease.
Ambrx is advancing a robust portfolio of clinical and preclinical
programs designed to optimize efficacy, safety and ease of use, in
multiple therapeutic areas, including its lead product candidate
ARX788. In addition, the company has collaborations with Bristol
Myers Squibb, BeiGene, Sino Biopharma, and NovoCodex, for drug
candidates generated using Ambrx technology. For additional
information, please visit www.ambrx.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements” within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Ambrx’s plans, the
future development and potential of Ambrx’s product candidates, and
expected contributions of Ms. Nelson. The words “anticipate,”
“estimate,” “expect,” “intend,” “may,” “should,” “target,” “would”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: risks associated with
preclinical and clinical development, whether Ambrx will be able to
access sufficient funding to execute its business plan, the fact
that future clinical results may be inconsistent with prior
results, and other factors discussed in the “Risk Factors” section
of Ambrx’s registration statement on Form F-1 filed with the
Securities and Exchange Commission. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Ambrx specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210630005273/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 laurence@gilmartinir.com
MEDIA Ian Stone Managing Director Canale Communications (619)
849-5388 ian.stone@canalecomm.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024